RxDoctor Payments DataLook up a doctor →

Jess Youngblood, MD

General Practice · Guntersville, ALNPI 1467676676

Payments from drug & device makers

$11,999in general payments, 2019–2025

Across 797 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • GSK$2K
  • AstraZeneca$1K
  • Novo Nordisk$759
  • Pfizer$752
  • Lilly USA, LLC$666
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$11,993100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,999 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama

Medicare billing

Part B allowed, 2024
$60,238
Medicare patients
615
Services billed
2,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide210$290,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter237$200,801
FarxigaDapagliflozin Propanediol142$145,492
JardianceEmpagliflozin153$135,350
EliquisApixaban124$117,802
TrulicityDulaglutide77$100,757
OzempicSemaglutide83$92,359
LinzessLinaclotide74$75,073
JanuviaSitagliptin Phosphate58$63,840
VraylarCariprazine Hcl35$62,425
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$59,771
MyrbetriqMirabegron75$59,093
RybelsusSemaglutide29$56,993
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,227$55,633
XareltoRivaroxaban43$44,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$666$391,615287 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,347$218,525231 claims
GSKTrelegy Ellipta, Breo Ellipta$1,510$209,364249 claims
Novo NordiskOzempic, Rybelsus$759$149,352112 claims
Boehringer IngelheimJardiance, Spiriva Respimat$351$147,915165 claims
AbbVieLinzess, Vraylar$2,585$137,498109 claims
PfizerEliquis$752$117,802124 claims
MerckJanuvia, Janumet, Belsomra$184$93,79386 claims
Astellas Pharma US IncMyrbetriq$16$59,09375 claims
Johnson & JohnsonXarelto$118$44,15043 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$20,80514 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$148$18,01328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.

Other general practice in Guntersville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →